189 related articles for article (PubMed ID: 7055978)
1. Serum bile acid profiles in cerebrotendinous xanthomatosis.
Beppu T; Seyama Y; Kasama T; Serizawa S; Yamakawa T
Clin Chim Acta; 1982 Feb; 118(2-3):167-75. PubMed ID: 7055978
[TBL] [Abstract][Full Text] [Related]
2. A case of cerebrotendinous xanthomatosis: effects of ursodeoxycholic acid administration on serum bile acids and cholestanol.
Kimura S; Beppu T; Kugai N; Koide Y; Fujita T; Iida K; Yamashita N; Yamashita K; Seyama Y
Jpn J Med; 1982 Jul; 21(3):210-5. PubMed ID: 7143816
[TBL] [Abstract][Full Text] [Related]
3. Quantitative determination of individual non-sulfated bile acids and sulfated lithocholic acid in serum by mass fragmentography.
Beppu T; Seyama Y; Kasama T; Yamakawa T
J Biochem; 1981 Jun; 89(6):1963-73. PubMed ID: 7287668
[TBL] [Abstract][Full Text] [Related]
4. Cerebrotendinous xanthomatosis: reduced serum 26-hydroxycholesterol.
Javitt NB; Kok E; Cohen B; Burstein S
J Lipid Res; 1982 May; 23(4):627-30. PubMed ID: 7097127
[TBL] [Abstract][Full Text] [Related]
5. Transformation of 4-cholesten-3-one and 7 alpha-hydroxy-4-cholesten-3-one into cholestanol and bile acids in cerebrotendinous xanthomatosis.
Salen G; Shefer S; Tint GS
Gastroenterology; 1984 Aug; 87(2):276-83. PubMed ID: 6735073
[TBL] [Abstract][Full Text] [Related]
6. Hydrophilic 7 beta-hydroxy bile acids, lovastatin, and cholestyramine are ineffective in the treatment of cerebrotendinous xanthomatosis.
Batta AK; Salen G; Tint GS
Metabolism; 2004 May; 53(5):556-62. PubMed ID: 15131757
[TBL] [Abstract][Full Text] [Related]
7. Quantitative determination of bile acid glucuronides in serum by mass fragmentography.
Takikawa H; Otsuka H; Beppu T; Seyama Y; Yamakawa T
J Biochem; 1982 Oct; 92(4):985-98. PubMed ID: 7174649
[TBL] [Abstract][Full Text] [Related]
8. Bile acid therapies applied to patients suffering from cerebrotendinous xanthomatosis.
Koopman BJ; Wolthers BG; van der Molen JC; Waterreus RJ
Clin Chim Acta; 1985 Oct; 152(1-2):115-22. PubMed ID: 4053393
[TBL] [Abstract][Full Text] [Related]
9. Biosynthesis of bile acids in cerebrotendinous xanthomatosis. Relationship of bile acid pool sizes and synthesis rates to hydroxylations at C-12, C-25, and C-26.
Salen G; Shefer S; Tint GS; Nicolau G; Dayal B; Batta AK
J Clin Invest; 1985 Aug; 76(2):744-51. PubMed ID: 4031069
[TBL] [Abstract][Full Text] [Related]
10. Long-term treatment of cerebrotendinous xanthomatosis with chenodeoxycholic acid.
Berginer VM; Salen G; Shefer S
N Engl J Med; 1984 Dec; 311(26):1649-52. PubMed ID: 6504105
[TBL] [Abstract][Full Text] [Related]
11. Biochemical studies of inherited diseases related to abnormal cholesterol metabolism. I. High-performance liquid chromatographic analysis of bile alcohol glucuronides in cerebrotendinous xanthomatosis.
Ohshima A; Kuramoto T; Hoshita T
Biol Pharm Bull; 1994 May; 17(5):721-3. PubMed ID: 7920441
[TBL] [Abstract][Full Text] [Related]
12. Increased formation of ursodeoxycholic acid in patients treated with chenodeoxycholic acid.
Salen G; Tint GS; Eliav B; Deering N; Mosbach EH
J Clin Invest; 1974 Feb; 53(2):612-21. PubMed ID: 11344576
[TBL] [Abstract][Full Text] [Related]
13. Isotopomer spectral analysis of intermediates of cholesterol synthesis in patients with cerebrotendinous xanthomatosis.
Clarenbach JJ; Lindenthal B; Dotti MT; Federico A; Kelleher JK; von Bergmann K
Metabolism; 2005 Mar; 54(3):335-44. PubMed ID: 15736111
[TBL] [Abstract][Full Text] [Related]
14. Serum concentrations of bile acid glucuronides in hepatobiliary diseases.
Takikawa H; Otsuka H; Beppu T; Seyama Y; Yamakawa T
Digestion; 1983; 27(4):189-95. PubMed ID: 6653918
[TBL] [Abstract][Full Text] [Related]
15. Reduction of urinary bile alcohol excretion and serum cholestanol in patients with cerebrotendinous xanthomatosis after oral administration of deoxycholic acid.
Wolthers BG; van der Molen JC; Walrecht H; Hesselmans LF
Clin Chim Acta; 1990 Dec; 193(3):113-8. PubMed ID: 2282689
[TBL] [Abstract][Full Text] [Related]
16. Abnormal urinary bile acids in a patient suffering from cerebrotendinous xanthomatosis during oral administration of ursodeoxycholic acid.
Koopman BJ; Wolthers BG; van der Molen JC; Nagel GT; Kruizinga W
Biochim Biophys Acta; 1987 Feb; 917(2):238-46. PubMed ID: 3801500
[TBL] [Abstract][Full Text] [Related]
17. Cerebrotendinous xanthomatosis: a review of biochemical findings of the patient population in The Netherlands.
Koopman BJ; Wolthers BG; van der Molen JC; van der Slik W; Waterreus RJ; van Spreeken A
J Inherit Metab Dis; 1988; 11(1):56-75. PubMed ID: 3128689
[TBL] [Abstract][Full Text] [Related]
18. Role of the 26-hydroxylase in the biosynthesis of bile acids in the normal state and in cerebrotendinous xanthomatosis. An in vivo study.
Björkhem I; Fausa O; Hopen G; Oftebro H; Pedersen JI; Skrede S
J Clin Invest; 1983 Jan; 71(1):142-8. PubMed ID: 6848555
[TBL] [Abstract][Full Text] [Related]
19. Diagnosis of cerebrotendinous xanthomatosis (CTX) and effect of chenodeoxycholic acid therapy by analysis of urine using capillary gas chromatography.
Wolthers BG; Volmer M; van der Molen J; Koopman BJ; de Jager AE; Waterreus RJ
Clin Chim Acta; 1983 Jun; 131(1-2):53-65. PubMed ID: 6883710
[TBL] [Abstract][Full Text] [Related]
20. Effect of chenodeoxycholic acid on biliary and urinary bile acids and bile alcohols in cerebrotendinous xanthomatosis; monitoring by high performance liquid chromatography.
Batta AK; Shefer S; Batta M; Salen G
J Lipid Res; 1985 Jun; 26(6):690-8. PubMed ID: 4031647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
